Nucleic Acids Research Advance Access originally published online on August 31, 2006
Nucleic Acids Research 2006 34(16):4467-4476; doi:10.1093/nar/gkl589
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nucleic Acids Research, 2006, Vol. 34, No. 16 4467-4476
© 2006 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
RNA |
Competition for RISC binding predicts in vitro potency of siRNA
ISIS Pharmaceuticals, Carlsbad Research Center 1896 Rutherford Road, Carlsbad, CA 92008, USA
*To whom correspondence should be addressed. Tel: +1 760 603 2618; Fax: +1 760 268 4989; Email: ekoller{at}isisph.com
Received June 8, 2006. Revised July 31, 2006. Accepted August 1, 2006.
Short interfering RNAs (siRNA) guide degradation of target RNA by the RNA-induced silencing complex (RISC). The use of siRNA in animals is limited partially due to the short half-life of siRNAs in tissues. Chemically modified siRNAs are necessary that maintain mRNA degradation activity, but are more stable to nucleases. In this study, we utilized alternating 2'-O-methyl and 2'-deoxy-2'-fluoro (OMe/F) chemically modified siRNA targeting PTEN and Eg5. OMe/F-modified siRNA consistently reduced mRNA and protein levels with equal or greater potency and efficacy than unmodified siRNA. We showed that modified siRNAs use the RISC mechanism and lead to cleavage of target mRNA at the same position as unmodified siRNA. We further demonstrated that siRNAs can compete with each other, where highly potent siRNAs can compete with less potent siRNAs, thus limiting the ability of siRNAs with lower potency to mediate mRNA degradation. In contrast, a siRNA with low potency cannot compete with a highly efficient siRNA. We established a correlation between siRNA potency and ability to compete with other siRNAs. Thus, siRNAs that are more potent inhibitors for mRNA destruction have the potential to out-compete less potent siRNAs indicating that the amount of a cellular component, perhaps RISC, limits siRNA activity.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. L. Snyder, I. Ahmed, and L. F. Steel RNA polymerase III can drive polycistronic expression of functional interfering RNAs designed to resemble microRNAs Nucleic Acids Res., October 1, 2009; 37(19): e127 - e127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Vickers, W. F. Lima, J. G. Nichols, and S. T. Crooke Reduced levels of Ago2 expression result in increased siRNA competition in mammalian cells Nucleic Acids Res., October 8, 2007; 35(19): 6598 - 6610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jagannath and M. Wood RNA interference based gene therapy for neurological disease Brief Funct Genomic Proteomic, May 3, 2007; (2007) elm005v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Matveeva, Y. Nechipurenko, L. Rossi, B. Moore, P. Saetrom, A. Y. Ogurtsov, J. F. Atkins, and S. A. Shabalina Comparison of approaches for rational siRNA design leading to a new efficient and transparent method Nucleic Acids Res., April 10, 2007; (2007) gkm088v1. [Abstract] [Full Text] [PDF]
|
|